2024/06/24

Shionogi Inc. Appoints David Benadon Senior Vice President, Chief Human Resources Officer

FLORHAM PARK, NJ, June 24, 2024 - Shionogi Inc., a U.S. subsidiary of Shionogi & Co., Ltd. (Head Office: Osaka, Japan; President and CEO: Isao Teshirogi, Ph.D.; hereinafter “Shionogi”), announced the appointment of David Benadon as Senior Vice President, Chief Human Resources Officer. Benadon brings more than 30 years of human resources and organizational leadership including the last 20 years within the pharmaceutical industry.
“David’s philosophy, which centers on integrating HR to the business, was a key factor in our decision to bring him to Shionogi as a member of our executive leadership team. He brings a strong track record of building and maintaining high-performing teams during times of growth while ensuring overall organizational effectiveness,” said Nate McCutcheon, President and Chief Executive Officer, Shionogi Inc. “Our success is built on our products and our people. In addition to our marketed antibiotic for the treatment of certain Gram-negative bacterial infections, we have a maturing development pipeline and an active global business development function. Under David’s leadership, I’m confident we’ll continue to attract, retain, and develop our team to drive our business as we grow our presence in the U.S.”
Benadon joins Shionogi Inc. from Oyster Point Pharma, where he served as the Chief Human Resources Officer and led the company through their early commercial launch phase to becoming a part of the global healthcare company Viatris.
“Shionogi is in such an interesting growth phase with both products and people. The team includes a diverse mix of long-term high-performing employees and promising new senior arrivals with deep expertise in infectious and rare disease, as well as several U.S.-based teams leading key global functions,” said Benadon. “I’m ready to quickly immerse myself into the business and culture and excited to contribute to the company’s continued success.”
Prior to his role at Oyster Point Pharma, David served as the U.S. Head of Human Resources at Insmed Incorporated. He also held human resources leadership positions at Novartis Oncology and Daiichi Sankyo, Inc. In these roles, Benadon has focused on cultural transformation, leadership development, performance management, recruitment, retention and recognition.
Benadon received his Bachelor of Science from the University of Rhode Island.

About Shionogi Inc.

Shionogi Inc. is a U.S. subsidiary of Shionogi & Co., Ltd., a Japanese research-driven pharmaceutical company. Since 1878, we have been harnessing the full potential of science to address global health challenges. Over the past six decades, we have discovered several novel antibiotics and medications for HIV and influenza. Today, we're building on our scientific legacy by conducting ongoing research into established products and new antibiotic compounds, as well as developing an investigational antiviral for COVID-19. Beyond infectious disease, our pipeline includes clinical programs in Fragile X syndrome, acute ischemic stroke, obesity and oncology. Learn more at Shionogi.com.

About Shionogi & Co. Ltd.

Shionogi & Co., Ltd. is a 145-year-old global, research-driven pharmaceutical company headquartered in Osaka, Japan, that is dedicated to bringing benefits to patients based on its corporate philosophy of “supplying the best possible medicine to protect the health and wellbeing of the patients we serve.” The company currently markets products in several therapeutic areas including anti-infectives, pain, CNS disorders, cardiovascular diseases and gastroenterology. Shionogi’s research and development currently target two therapeutic areas: infectious diseases, and pain/CNS disorders.
For more information on Shionogi & Co., Ltd., please visit https://www.shionogi.com/global/en.html.

Forward-Looking Statements

This announcement contains forward-looking statements. These statements are based on expectations in light of the information currently available, assumptions that are subject to risks and uncertainties which could cause actual results to differ materially from these statements. Risks and uncertainties include general domestic and international economic conditions such as general industry and market conditions, and changes of interest rate and currency exchange rate. These risks and uncertainties particularly apply with respect to product-related forward-looking statements. Product risks and uncertainties include, but are not limited to, completion and discontinuation of clinical trials; obtaining regulatory approvals; claims and concerns about product safety and efficacy; technological advances; adverse outcome of important litigation; domestic and foreign healthcare reforms and changes of laws and regulations. Also for existing products, there are manufacturing and marketing risks, which include, but are not limited to, inability to build production capacity to meet demand, lack of availability of raw materials and entry of competitive products. The company disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.
For Further Information, Contact: